PillRx only · Tablet, Chewable · Oral
Lisdexamfetamine Dimesylate
Brands: Vyvanse · Lisdexamfetamine Dimesylate
7 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US42 NDCs
7 active makers
7 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
ATC—
RxCUI (US)—
US makers7 labelers
Packages42
DEA / ScheduleCII
US acquisition costNADAC · per unit
Average across 42 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$5.200
Latest avg · Jun 17, 2026
-24%
Since Dec 17, 2025
7
Active US suppliers
29%
Top-2 supplier share*
Who makes it7 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Novadoz Pharmaceuticals LLC | unknown | 6 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | unknown | 6 | SUPPLYING |
| SpecGx LLC | unknown | 6 | SUPPLYING |
| Takeda Pharmaceuticals America, Inc. | unknown | 6 | SUPPLYING |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | unknown | 6 | SUPPLYING |
| Granules Pharmaceuticals Inc | unknown | 6 | SUPPLYING |
| Camber Pharmaceuticals, Inc. | unknown | 6 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.